ロード中...
Molecular Monitoring in Chronic Myeloid Leukemia: Response to Tyrosine Kinase Inhibitors and Prognostic Implications
The majority of patients with chronic-phase (CP) chronic myeloid leukemia (CML) who are treated with Bcr-Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve cytogenetic disease remission (ie, Philadelphia chromosome-positive cells undetectable by cytogenetic evaluation). However, m...
保存先:
| 出版年: | Cancer |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2008
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5141579/ https://ncbi.nlm.nih.gov/pubmed/18348294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23427 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|